SCHEMBL3005809

SCHEMBL3005809

COc1ccc(S(=O)(=O)C2CCN(c3nc(-c4c(C)cc(C)cc4C)cs3)CC2)c(OC)c1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.43
SMN1; SMN2 Q16637 5/20 0.43
MAPT P10636 9/20 0.42
LMNA P02545 5/20 0.41
TDP1 Q9NUW8 1/20 0.41
NPC1 O15118 4/20 0.40
REV1 Q9UBZ9 1/20 0.39
ALDH1A1 P00352 6/20 0.39
HSD17B10 Q99714 4/20 0.39
MAPK1 P28482 4/20 0.39
TP53 P04637 3/20 0.39
USP2 O75604 1/20 0.39
RECQL P46063 1/20 0.39
TSHR P16473 1/20 0.39
AR P10275 1/20 0.38
HTT P42858 2/20 0.38
GAA P10253 2/20 0.37
HPGD P15428 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3019095 0.93 RAB9A (0.46) RAB9ASMN1; SMN2MAPTLMNATDP1
SCHEMBL3011340 0.93 RAB9A (0.46) RAB9ASMN1; SMN2MAPTLMNATDP1
SCHEMBL3010353 0.90 SMN1; SMN2 (0.48) RAB9ASMN1; SMN2MAPTLMNATDP1
SCHEMBL3016315 0.88 SMN1; SMN2 (0.53) RAB9ASMN1; SMN2MAPTLMNATDP1
SCHEMBL3014342 0.88 AR (0.52) RAB9ASMN1; SMN2MAPTLMNATDP1
SCHEMBL3022472 0.87 AR (0.52) RAB9ASMN1; SMN2MAPTLMNATDP1
SCHEMBL3004108 0.87 SMN1; SMN2 (0.48) RAB9ASMN1; SMN2MAPTLMNANPC1
SCHEMBL3007225 0.87 SMN1; SMN2 (0.58) RAB9ASMN1; SMN2MAPTLMNATDP1
SCHEMBL2999403 0.86 SMN1; SMN2 (0.49) RAB9ASMN1; SMN2MAPTLMNATDP1
SCHEMBL3006113 0.86 MAPT (0.46) RAB9ASMN1; SMN2MAPTLMNATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA RAB9A 2943/4885SMN1; SMN2 1/4885MAPT 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.